Present at the largest biotechnology event

The need for European funding in biotechnology is very strong and is recognized by the European Commission itself, mainly due to the following aspects:

• High R&D costs: The development of new therapies, biotechnology platforms or biomanufacturing processes requires investments that a single company can hardly cover.
• High risk: Many biotech startups and SMEs have great potential, but high technological and market risk, which makes it difficult to attract private investment without public support.
• Industrial scale-up: Moving from laboratory to pilot and industrial is expensive (platforms, bioreactors, clinical trials) and requires long-term funding.
• Global competitiveness: To avoid falling behind the USA or Asia, Europe must strengthen its biotech fabric with programs that give innovative companies muscle.

The areas in which funding is most needed have been identified.

• Biotechnology in health: advanced therapies, vaccines, gene editing, biomolecule production, personalized medicine.
• Circular bioeconomy: waste recovery, bioproducts, biodegradable plastics, green chemistry.
• Agriculture and food: biotechnology applied to resistant crops, alternative proteins, precision fermentation.
• Biomanufacturing: new platforms for large-scale production with cleaner and more sustainable processes.

To this end, the European Union has implemented a series of R&D&I financing instruments.

• Horizon Europe: dedicates specific funds to biotechnology in health, food, bioeconomy and the environment.
• EIC (European Innovation Council): finances startups with high disruptive potential.
• CBE JU (Circular Bio-based Europe)promotes industrial projects for the bioeconomy.

With these instruments, the European Union aims to boost innovation, facilitating the creation of spin-offs and deeptech startups, contributing to European technological sovereignty: by reducing dependence on imports of key medicines, ingredients or materials. It is also expected to create new skilled jobs in science, engineering and advanced production.

Euro-Funding is going to be present at the next edition of BIOSPAINrepresented by Oscar Salazar, Director of European Funds and Elena Perez, Senior Consultant, contributing with our knowledge to the European fundraising within the biotechnology sector. BIOSPAIN is one of the largest biotechnology events in Europe, organized by ASEBIO, next October 7-9 in Barcelona.